← Back to search
PEPTILOGICS INC
PITTSBURGH, PA, 15203
UnclaimedClaim this profile (free)
Subcontracting experience
3 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | PEPTILOGICS IS A BIOTECHNOLOGY COMPANY THAT UTILIZES AN INNOVATIVE PLATFORM TO DEVELOP NOVEL PEPTIDE THERAPEUTICS TO ADDRESS UNMET MEDICAL NEEDS. OUR PIPELINE INCLUDES A NOVEL CLASS OF ENGINEERED CATIONIC ANTIBIOTIC PEPTIDES. OUR LEAD CANDIDATE, PLG0206, BASED ON NATURALLY OCCURRING ANTIMICROBIAL PEPTIDES, EXHIBITS BROAD-SPECTRUM ACTIVITY AGAINST CLINICALLY IMPORTANT MDR GRAM-POSITIVE (S. AUREUS, INCLUDING MRSA, AND E. FAECIUM, INCLUDING VRE) AND GRAM-NEGATIVE (P. AERUGINOSA, E. COLI, AND A. BAUMANNII) PATHOGENS. PLG0206 EXHIBITS THE ABILITY TO RAPIDLY INACTIVATE BOTH PLANKTONIC AND BIOFILM PATHOGENS. THIS WITH ITS BROAD-SPECTRUM ACTIVITY MAKE IT AN IDEAL DEVELOPMENT CANDIDATE FOR PREVENTING INVASIVE INFECTIONS. PLG0206 TARGETS AND DISRUPTS THE BACTERIAL MEMBRANE, CAUSING RAPID BACTERIAL DEATH VIA CELLULAR CHEMICAL IMBALANCE. SINCE BACTERIAL MEMBRANES ARE A CONSERVED EVOLUTIONARY TARGET, THIS MOA APPEARS TO LIMIT THE RISK FOR RESISTANCE COMPARED TO OTHER ANTIBIOTICS. WITH RAPID BACTERICIDAL AND ANTI-BIOFILM ACTIVITY ON CONTACT, PLG0206 IS BEING DEVELOPED FOR THE PREVENTION OF TRAUMATIC FRACTURE-RELATED INFECTIONS (FRI) VIA LOCAL ADMINISTRATION IN CONJUNCTION STANDARD SURGICAL CARE. FRI IS A SERIOUS, LIFE-THREATENING INFECTION WITH SIGNIFICANT ECONOMIC BURDEN. FRI TREATMENT REQUIRES HOSPITALIZATION AND ONE OR MORE REPEAT SURGICAL PROCEDURES. MICROORGANISMS THAT CAUSE FRI INCLUDE S. AUREUS, COAGULATE-NEGATIVE STAPHYLOCOCCUS SPP., ENTEROCOCCUS SPP., AND AEROBIC GRAM-NEGATIVE BACILLI. THE POTENTIAL INFECTING PATHOGEN IS UNKNOWN AT THE TIME OF TRAUMATIC INSULT AND INITIAL SURGERY. CLINICAL PRACTICE GUIDELINES RECOMMEND 2-5 DAYS OF SYSTEMIC ANTIBIOTICS FOLLOWING TRAUMATIC INJURY TO PREVENT FRI. DESPITE THIS, TRAUMATIC FRACTURES HAVE A HIGH INFECTION RATE (UP TO 40%). FRI OFTEN REQUIRES MULTIPLE SURGICAL PROCEDURES, LEADING TO SUBSTANTIAL MORBIDITY AND MORTALITY WITH AN UP TO 25% 5-YEAR MORTALITY RISK. CURRENT STRATEGIES DO NOT ADEQUATELY PREVENT THE INFECTIONS THAT LEAD TO FRI'S HIGH MORBIDITY AND MORTALITY BURDEN, AND FRI REMAINS AN UNMET MEDICAL NEED AND REQUIRES A DIFFERENT APPROACH TO THAT CURRENTLY EMPLOYED. PLG0206, ADMINISTERED AT THE TIME OF INJURY, THROUGH ITS RAPIDLY ACTING BROAD-SPECTRUM ACTIVITY AGAINST THE PATHOGENS COMMONLY CAUSING FRI HAS THE POTENTIAL TO ADDRESS THIS UNMET NEED. PLG0206 WILL BE ADMINISTERED FOLLOWING TRAUMATIC INJURY IN THE OPERATING THEATER AFTER SURGICAL DEBRIDEMENT AND BONE FIXATION AS A LONG-ACTING CONTROLLED RELEASE FORMULATION. IT IS EXPECTED TO BE MORE EFFECTIVE THAN THE CURRENT STANDARD OF CARE BY PROVIDING LONG-LASTING PATHOGEN-INACTIVATING DRUG LEVELS TO PREVENT INFECTION NIDI (DEVITALIZED AND CONTAMINATED BONE AND SOFT TISSUE AND METAL FIXATION DEVICES) THAT LEAD TO INVASIVE INFECTION. THE EXPECTED LIMITED SYSTEMIC EXPOSURE WITH LOCAL DRUG DEPOT SHOULD ENSURE A GOOD SAFETY PROFILE. THE DEVELOPMENT PLAN WILL ASSESS THE IN VITRO AND IN VIVO RELEASE CHARACTERISTICS OF VARIOUS PLG0206 CONTROLLED-RELEASE FORMULATIONS ALONG WITH PK, TOLERABILITY, AND EFFICACY IN ANIMAL MODELS OF FRI. ADDITIONAL STUDIES WILL IDENTIFY THE MOST EFFECTIVE, WELL-TOLERATED CONCENTRATION TO BE USED IN HUMAN TRIALS TO ESTABLISH SAFETY AND EFFICACY OF LOCAL ADMINISTRATION IN THE PREVENTION OF FRI IN CONJUNCTION WITH CURRENT STANDARD OF CARE. KC3965 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $1,520,300 | Dec 6, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | PEPTILOGICS IS A BIOTECHNOLOGY COMPANY THAT UTILIZES AN INNOVATIVE PLATFORM TO DEVELOP NOVEL PEPTIDE THERAPEUTICS TO ADDRESS UNMET MEDICAL NEEDS. OUR PIPELINE INCLUDES A NOVEL CLASS OF ENGINEERED CATIONIC ANTIBIOTIC PEPTIDES. OUR LEAD CANDIDATE, PLG0206, BASED ON NATURALLY OCCURRING ANTIMICROBIAL PEPTIDES, EXHIBITS BROAD-SPECTRUM ACTIVITY AGAINST CLINICALLY IMPORTANT MDR GRAM-POSITIVE (S. AUREUS, INCLUDING MRSA, AND E. FAECIUM, INCLUDING VRE) AND GRAM-NEGATIVE (P. AERUGINOSA, E. COLI, AND A. BAUMANNII) PATHOGENS. PLG0206 EXHIBITS THE ABILITY TO RAPIDLY ADDRESS BIOFILM PATHOGENS, MAKING IT AN IDEAL CANDIDATE FOR TREATMENT OF BIOFILM-ASSOCIATED INFECTIONS. PLG0206 TARGETS AND DISRUPTS THE BACTERIAL MEMBRANE, CAUSING RAPID BACTERIAL DEATH VIA CELLULAR CHEMICAL IMBALANCE. SINCE BACTERIAL MEMBRANES ARE A CONSERVED EVOLUTIONARY TARGET, THIS MOA APPEARS TO LIMIT THE RISK FOR RESISTANCE COMPARED TO OTHER ANTIBIOTICS. WITH RAPID BACTERICIDAL AND ANTI-BIOFILM ACTIVITY ON CONTACT, PLG0206 IS BEING DEVELOPED FOR THE TREATMENT OF INFECTIONS ASSOCIATED WITH PROSTHETIC JOINTS (PJI) VIA LOCAL ADMINISTRATION IN CONJUNCTION WITH AN IRRIGATION AND DEBRIDEMENT (I&D) PROCEDURE AND STANDARD-OF-CARE ANTIBIOTIC THERAPY. PJI IS A SERIOUS, LIFE-THREATENING INFECTION WITH SIGNIFICANT ECONOMIC BURDEN. PJI TREATMENT REQUIRES HOSPITALIZATION AND ONE OR MORE REPEAT SURGICAL PROCEDURES. MICROORGANISMS THAT CAUSE PJI INCLUDE S. AUREUS, ENTEROCOCCUS SPP., AND AEROBIC GRAM-NEGATIVE BACILLI. A THIRD OF INFECTIONS ARE POLYMICROBIAL AND REQUIRE BROAD SPECTRUM ANTIMICROBIAL THERAPY. CLINICAL PRACTICE GUIDELINES RECOMMEND RETENTION OF THE CURRENT PROSTHESIS IF PATIENTS PRESENT WITH SIGNS OF EARLY INFECTION. HOWEVER, CURRENT PJI TREATMENT HAS A HIGH FAILURE RATE, AND OFTEN REQUIRES ADDITIONAL FOLLOW-ON SURGICAL PROCEDURES, LEADING TO SUBSTANTIAL MORBIDITY AND MORTALITY, WITH A 20% 5-YEAR MORTALITY RISK. CURRENT ANTIBIOTICS ARE POORLY EFFECTIVE IN THE PRESENCE OF BIOFILM AND ROUTINELY FAIL TO ERADICATE PERSISTER PATHOGENS THAT RESIDE WITHIN THE BIOFILM. PJI REMAINS AN UNMET MEDICAL NEED AND REQUIRES A DIFFERENT APPROACH TO THAT CURRENTLY EMPLOYED. PLG0206, THROUGH ITS RAPIDLY ACTING BROAD-SPECTRUM ACTIVITY AGAINST THE PATHOGENS COMMONLY CAUSING PJI, AND IN THE PRESENCE OF BIOFILM, HAS THE POTENTIAL TO ADDRESS THIS UNMET NEED. PLG0206 ADMINISTERED DURING AN I&D PROCEDURE AS AN INTRAOPERATIVE IRRIGATION SOLUTION IS EXPECTED TO BE MORE EFFECTIVE THAN STANDARD ANTIBIOTIC THERAPY ALONE BECAUSE OF THE HIGH LOCAL CONCENTRATIONS THAT CAN BE ACHIEVED AND ITS ABILITY TO RAPIDLY ELIMINATE BIOFILM-ASSOCIATED PATHOGENS WITH DIRECT CONTACT. THE EXPECTED LIMITED SYSTEMIC EXPOSURE WITH LOCAL JOINT IRRIGATION SHOULD ENSURE A GOOD SAFETY PROFILE. SAFETY HAS ALREADY BEEN DOCUMENTED IN MULTIPLE SAFETY AND TOLERABILITY NONCLINICAL ANIMAL STUDIES INCLUDING GLP TOXICOLOGY. IN ADDITION, AN INTRAVENOUS HUMAN PHASE 1 SINGLE ASCENDING DOSE TRIAL IN HEALTHY VOLUNTEERS WAS SUCCESSFULLY COMPLETED. SINCE THEN, PEPTILOGICS HAS SECURED AN €œALLOWED TO PROCEED€Ͽ½ STATUS FROM THE FDA FOLLOWING A SUCCESSFUL IND SUBMISSION. PEPTILOGICS IS CURRENTLY ENROLLING HUMAN SUBJECTS IN A PHASE 1B CLINICAL TRIAL TO ASSESS SAFETY AND TOLERABILITY OF PLG0206 AS A SURGICAL WASH (IRRIGANT) IN THE TREATMENT OF POSTOPERATIVE PERIPROSTHETIC JOINT INFECTION AFTER TOTAL KNEE ARTHROPLASTY (TKA). PLG0206 WILL BE ADMINISTERED AS A LOCAL IRRIGATION SOLUTION IN PJI SURGERY AS AN ADJUNCT THERAPY TO THE STANDARD SURGICAL CARE AND SYSTEMIC ANTIBIOTIC TREATMENT REGIMEN. THE GOAL BEING A SINGLE OPERATIVE, HARDWARE RETENTION, AND A RAPID RETURN TO FULL FUNCTIONAL CAPACITY. 4500004364 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $50,000 | Sep 15, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | PEPTILOGICS IS A BIOTECHNOLOGY COMPANY THAT UTILIZES AN INNOVATIVE PLATFORM TO DEVELOP NOVEL PEPTIDE THERAPEUTICS TO ADDRESS UNMET MEDICAL NEEDS. OUR PIPELINE INCLUDES A NOVEL CLASS OF ENGINEERED CATIONIC ANTIBIOTIC PEPTIDES. OUR LEAD CANDIDATE, PLG0206, BASED ON NATURALLY OCCURRING ANTIMICROBIAL PEPTIDES, EXHIBITS BROAD-SPECTRUM ACTIVITY AGAINST CLINICALLY IMPORTANT MDR GRAM-POSITIVE (S. AUREUS, INCLUDING MRSA, AND E. FAECIUM, INCLUDING VRE) AND GRAM-NEGATIVE (P. AERUGINOSA, E. COLI, AND A. BAUMANNII) PATHOGENS. PLG0206 EXHIBITS THE ABILITY TO RAPIDLY ADDRESS BIOFILM PATHOGENS, MAKING IT AN IDEAL CANDIDATE FOR TREATMENT OF BIOFILM-ASSOCIATED INFECTIONS.
PLG0206 TARGETS AND DISRUPTS THE BACTERIAL MEMBRANE, CAUSING RAPID BACTERIAL DEATH VIA CELLULAR CHEMICAL IMBALANCE. SINCE BACTERIAL MEMBRANES ARE A CONSERVED EVOLUTIONARY TARGET, THIS MOA APPEARS TO LIMIT THE RISK FOR RESISTANCE COMPARED TO OTHER ANTIBIOTICS. WITH RAPID BACTERICIDAL AND ANTI-BIOFILM ACTIVITY ON CONTACT, PLG0206 IS BEING DEVELOPED FOR THE TREATMENT OF INFECTIONS ASSOCIATED WITH PROSTHETIC JOINTS (PJI) VIA LOCAL ADMINISTRATION IN CONJUNCTION WITH AN IRRIGATION AND DEBRIDEMENT (I&D) PROCEDURE AND STANDARD-OF-CARE ANTIBIOTIC THERAPY.
PJI IS A SERIOUS, LIFE-THREATENING INFECTION WITH SIGNIFICANT ECONOMIC BURDEN. PJI TREATMENT REQUIRES HOSPITALIZATION AND ONE OR MORE REPEAT SURGICAL PROCEDURES. MICROORGANISMS THAT CAUSE PJI INCLUDE S. AUREUS, ENTEROCOCCUS SPP., AND AEROBIC GRAM-NEGATIVE BACILLI. A THIRD OF INFECTIONS ARE POLYMICROBIAL AND REQUIRE BROAD SPECTRUM ANTIMICROBIAL THERAPY. CLINICAL PRACTICE GUIDELINES RECOMMEND RETENTION OF THE CURRENT PROSTHESIS IF PATIENTS PRESENT WITH SIGNS OF EARLY INFECTION. HOWEVER, CURRENT PJI TREATMENT HAS A HIGH FAILURE RATE, AND OFTEN REQUIRES ADDITIONAL FOLLOW-ON SURGICAL PROCEDURES, LEADING TO SUBSTANTIAL MORBIDITY AND MORTALITY, WITH A 20% 5-YEAR MORTALITY RISK. CURRENT ANTIBIOTICS ARE POORLY EFFECTIVE IN THE PRESENCE OF BIOFILM AND ROUTINELY FAIL TO ERADICATE PERSISTER PATHOGENS THAT RESIDE WITHIN THE BIOFILM. PJI REMAINS AN UNMET MEDICAL NEED AND REQUIRES A DIFFERENT APPROACH TO THAT CURRENTLY EMPLOYED. PLG0206, THROUGH ITS RAPIDLY ACTING BROAD-SPECTRUM ACTIVITY AGAINST THE PATHOGENS COMMONLY CAUSING PJI, AND IN THE PRESENCE OF BIOFILM, HAS THE POTENTIAL TO ADDRESS THIS UNMET NEED.
PLG0206 ADMINISTERED DURING AN I&D PROCEDURE AS AN INTRAOPERATIVE IRRIGATION SOLUTION IS EXPECTED TO BE MORE EFFECTIVE THAN STANDARD ANTIBIOTIC THERAPY ALONE BECAUSE OF THE HIGH LOCAL CONCENTRATIONS THAT CAN BE ACHIEVED AND ITS ABILITY TO RAPIDLY ELIMINATE BIOFILM-ASSOCIATED PATHOGENS WITH DIRECT CONTACT. THE EXPECTED LIMITED SYSTEMIC EXPOSURE WITH LOCAL JOINT IRRIGATION SHOULD ENSURE A GOOD SAFETY PROFILE.
SAFETY HAS ALREADY BEEN DOCUMENTED IN MULTIPLE SAFETY AND TOLERABILITY NONCLINICAL ANIMAL STUDIES INCLUDING GLP TOXICOLOGY. IN ADDITION, AN INTRAVENOUS HUMAN PHASE 1 SINGLE ASCENDING DOSE TRIAL IN HEALTHY VOLUNTEERS WAS SUCCESSFULLY COMPLETED. SINCE THEN, PEPTILOGICS HAS SECURED AN €œALLOWED TO PROCEED€Ͽ½ STATUS FROM THE FDA FOLLOWING A SUCCESSFUL IND SUBMISSION. PEPTILOGICS IS CURRENTLY ENROLLING HUMAN SUBJECTS IN A PHASE 1B CLINICAL TRIAL TO ASSESS SAFETY AND TOLERABILITY OF PLG0206 AS A SURGICAL WASH (IRRIGANT) IN THE TREATMENT OF POSTOPERATIVE PERIPROSTHETIC JOINT INFECTION AFTER TOTAL KNEE ARTHROPLASTY (TKA). PLG0206 WILL BE ADMINISTERED AS A LOCAL IRRIGATION SOLUTION IN PJI SURGERY AS AN ADJUNCT THERAPY TO THE STANDARD SURGICAL CARE AND SYSTEMIC ANTIBIOTIC TREATMENT REGIMEN. THE GOAL BEING A SINGLE OPERATIVE, HARDWARE RETENTION, AND A RAPID RETURN TO FULL FUNCTIONAL CAPACITY. 4500004364 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $909,924 | Oct 6, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.